Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
Wang R, Zhang C, Cao Y, Wang J, Jiao S, Zhang J, Wang M, Tang P, Ouyang Z, Liang W, Mao Y, Wang A, Li G, Zhang J, Wang M, Wang S, Gui X.
Wang R, et al. Among authors: wang j, wang m, wang s, wang a.
Theranostics. 2023 Jan 1;13(1):148-160. doi: 10.7150/thno.79367. eCollection 2023.
Theranostics. 2023.
PMID: 36593962
Free PMC article.